John Sampson, MD, Neurosurgery, Durham, NC, Duke University Hospital

JohnSampsonMDPhD, MBA

Neurosurgery Durham, NC

Brain & Spinal Tumor

Department Chair, Duke Neurosurgery

Dr. Sampson is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sampson's full profile

Already have an account?

Summary

  • Large research focus on immunotherapy for high grade glioma.

Education & Training

  • Fuqua School of Business, Duke UniversityOTHER_TRAINING
  • Duke University
    Duke UniversityOTHER_TRAINING
  • Duke University Hospital
    Duke University HospitalRESIDENCY
  • Duke University Hospital
    Duke University HospitalINTERNSHIP
  • University of Manitoba
    University of ManitobaMEDICAL_SCHOOL
  • St. John's College, University of ManitobaOTHER_TRAINING

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2014 - 2020
  • NC State Medical License
    NC State Medical License 1996 - 2021
  • American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • America's Top Surgeons SLD Industries, Inc., 2012
  • Fuqua Scholar Award Duke University, Fuqua School of Business, 2012
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease  
    Batich, K.B., St. Clair, E.W., McLendon, R.E., Sampson, J.H., J Clin Neurosci, 10/1/2013
  • Isocitrate dehydrogenase 1 (IDH1): What it means to the neurosurgeon  
    Hodges, T.R., Choi, B.D., Bigner, D.D., Yan, H., Sampson, J.H., J Neurosurg, 6/1/2013
  • Clinicopathological Characteristics and Treatment of Rhabdoid Glioblastoma  
    Babu, R., Hatef, J., McLendon, R., Cummings, T., Sampson, J.H., Friedman, A.H., Adamson, C., J Neurosurg, 5/3/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma.
    Cuneo, K.C., Cabrera, A.R., Sampson, J.H., Allen, K.J., Vredenburgh, J.J., Peters, K., Chang, Z., Herndon, J.E., Desjardins, A., Reardon, D.A., Kirkpatrick, J., J Clin Oncol, 1/1/2011
  • Concurrent Bevacizumab and Radiosurgery for Recurrent Malignant Glioma: Toxicity Results from a Prospective Pilot Study.
    Cuneo, K.C., Cabrera, A.R., Sampson, J.H., Allen, K., Duffy, E., Vredenburgh, J.J., Peters, K.B., Chang, Zheng, Desjardins, A., Kirkpatrick, J.P., ASTRO, Int J Radiat Oncol Biol Phys, 1/1/2011
  • Dendritic cell vaccines targeting cytomegalovirus in glioblastoma.
    Mitchell, D.A., Archer, G.E., Friedman, H.S., Herndon, J.E., Bigner, D.D., Sampson, J.H., 16th Annual Society for Neuro-oncology meeting, Neuro-oncol, 1/1/2011
  • Join now to see all

Lectures

  • Chimeric Antigen Receptor (CAR) and Adoptive Cell Transfer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
  • Novel role for enhancing immunotherapy against pediatric brain tumors using hematopoietic stem cells. 
    San Francisco, CA - 11/21/2013
  • Developmentally regulated antigens for immunologic targeting of medulloblastoma subtypes. 
    San Francisco, CA - 11/21/2013
  • Join now to see all

Other

  • Novel Therapies in the Management of Malignant Brain Tumors: Bevacizumab and Surgery. 
    Chang, S., Sampson, J.H., Aghi, M., Theodosopoulos, P.V., CNS Neurosurger Webinars, Controversies in Neuro-Oncology: An Academic- Community Forum
    1/12/2010
  • Cell-mediated immunotherapy of brain tumors. 
    Sampson, J.H., Doctoral Thesis Defense, Duke University
    12/5/1996

Press Mentions

  • Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting
    Medicenna Presents Late Breaking Abstract Updating Results from Phase 2b Recurrent GBM Trial at the 36th EORTC-NCI-AACR Meeting
  • Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting
    Medicenna Announces Upcoming Presentations at the EORTC-NCI-AACR Annual Meeting
  • Nanomaterials to Boost the Body’s Natural Defenses
    Nanomaterials to Boost the Body’s Natural DefensesOctober 29, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations